Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felty's syndrome.

Geza P Balint1, Peter V Balint

  • 1Fourth General Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, 25-29 Frankel L. St, 1023 Hungary. balintg@mail.datanet.hu

Best Practice & Research. Clinical Rheumatology
|September 30, 2004
PubMed
Summary

Felty's syndrome (FS) is a rare RA complication with severe joint issues and infections due to neutropenia. Treatments like DMARDs and G-CSF show promise, with splenectomy offering immediate neutropenia relief.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: How ultrasound changed the practice of rheumatology: echoes of a 30-year collaboration.

Zeitschrift fur Rheumatologie·2026
Same author

Understanding Calabar swellings: Assessing subcutaneous loiasis using ultrasound.

PLoS neglected tropical diseases·2026
Same author

How ultrasound changed the practice of rheumatology: echoes of a 30-year collaboration.

Zeitschrift fur Rheumatologie·2026
Same author

Enhancing rheumatology training: The POCRUS model for integrating ultrasound into clinical practice. (From APLAR imaging SIG).

International journal of rheumatic diseases·2024
Same author

Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis.

Annals of the rheumatic diseases·2024
Same author

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

Annals of the rheumatic diseases·2024

Area of Science:

  • Rheumatology
  • Immunology
  • Hematology

Background:

  • Felty's syndrome (FS) is a rare triad of rheumatoid arthritis (RA), neutropenia, and splenomegaly, affecting <1% of RA patients.
  • FS presents with severe joint destruction, significant extra-articular manifestations, and recurrent bacterial infections due to neutropenia.
  • Neutropenia in FS results from decreased granulopoiesis and increased peripheral granulocyte destruction, contributing to increased mortality.

Purpose of the Study:

  • To summarize the clinical characteristics, pathogenesis, and treatment options for Felty's syndrome.
  • To highlight the diagnostic markers and immunogenetic associations in FS patients.
  • To review the efficacy of current and emerging therapies for FS.

Main Methods:

  • Literature review of Felty's syndrome focusing on clinical presentation, etiology, and management.
  • Analysis of diagnostic criteria including rheumatoid factor (RF), antinuclear antibody (ANA), and HLA-DR4*0401 antigen.
  • Evaluation of treatment outcomes for disease-modifying anti-rheumatic drugs (DMARDs), granulocyte colony-stimulating factor (G-CSF), and splenectomy.

Main Results:

  • FS patients exhibit severe joint damage, extra-articular symptoms (nodules, vasculitis, ulcers), and high rates of RF and ANA positivity.
  • Neutropenia in FS is linked to decreased granulopoiesis and increased granulocyte destruction, with some patients showing large granular lymphocyte (LGL) expansion.
  • Methotrexate (MTX) is an effective DMARD for FS neutropenia; G-CSF shows encouraging results, and splenectomy provides rapid neutropenia improvement but less impact on infection rates.

Conclusions:

  • Felty's syndrome requires comprehensive management addressing both rheumatologic and hematologic aspects.
  • Early diagnosis and appropriate treatment, including DMARDs and potentially G-CSF or splenectomy, are crucial for improving outcomes and reducing mortality.
  • Further research into biological agents is warranted for managing this complex RA subset.

Related Experiment Videos